Trans-2-Phenylcyclopropylamine

Identification

Name
Trans-2-Phenylcyclopropylamine
Accession Number
DB02665  (EXPT03088)
Type
Small Molecule
Groups
Experimental
Description

A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311)

Structure
Thumb
Synonyms
Not Available
Categories
UNII
Not Available
CAS number
Not Available
Weight
Average: 134.1983
Monoisotopic: 134.096974389
Chemical Formula
C9H12N
InChI Key
AELCINSCMGFISI-DTWKUNHWSA-O
InChI
InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2/p+1/t8-,9+/m0/s1
IUPAC Name
(1R,2S)-2-phenylcyclopropan-1-aminium
SMILES
[NH3+][[email protected]@H]1C[[email protected]]1C1=CC=CC=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UTrypsin-1Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Trans-2-Phenylcyclopropylamine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcarboseTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Trans-2-Phenylcyclopropylamine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Alaproclate.Experimental
AlbiglutideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Albiglutide.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
AliskirenTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Allopregnanolone.Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
AlogliptinTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Trans-2-Phenylcyclopropylamine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit, Investigational
AlprenololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Trans-2-Phenylcyclopropylamine.Approved
AmbrisentanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Amitriptyline.Approved
AmlodipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Amperozide.Experimental
AmphetamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Amphetamine.Approved, Illicit
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Arformoterol.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Trans-2-Phenylcyclopropylamine.Approved
AtenololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Atenolol.Approved
AtomoxetineTrans-2-Phenylcyclopropylamine may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Atropine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Azaperone.Investigational, Vet Approved
AzelastineTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Baclofen.Approved
BambuterolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Bambuterol.Approved, Investigational
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Trans-2-Phenylcyclopropylamine.Illicit
BenazeprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Trans-2-Phenylcyclopropylamine.Approved
BenzphetamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Benzyl alcohol.Approved
BepridilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Trans-2-Phenylcyclopropylamine.Approved
BetaxololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Betaxolol.Approved
BethanidineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Bezafibrate.Approved
BietaserpineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bisoprolol.Approved
BosentanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Trans-2-Phenylcyclopropylamine may increase the hypotensive activities of BQ-123.Investigational
BretyliumTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Brimonidine.Approved
BrofaromineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Bromisoval.Experimental
BromocriptineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
BupranololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit, Vet Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Trans-2-Phenylcyclopropylamine.Approved
CadralazineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Cadralazine.Experimental
CafedrineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Candoxatril.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Canertinib.Investigational
CaptoprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Trans-2-Phenylcyclopropylamine.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Carisoprodol.Approved
CaroxazoneTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Carteolol.Approved
CarvedilolTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Trans-2-Phenylcyclopropylamine.Approved
ChlorothiazideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Chlorphenamine.Approved
ChlorphentermineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
ChlorpropamideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational, Withdrawn
ChlorthalidoneTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Chlorzoxazone.Approved
CicletanineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Cilazapril.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
CirazolineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Citalopram.Approved
ClemastineTrans-2-Phenylcyclopropylamine may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClidiniumThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Clopenthixol.Experimental
CloranololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Trans-2-Phenylcyclopropylamine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
CryptenamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Cryptenamine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Trans-2-Phenylcyclopropylamine.Approved
CyclopenthiazideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineTrans-2-Phenylcyclopropylamine may increase the anticholinergic activities of Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Dantrolene.Approved
DapagliflozinTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Trans-2-Phenylcyclopropylamine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Dapoxetine.Investigational
DebrisoquinTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Delapril.Experimental
DeramciclaneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Deramciclane.Investigational
DeserpidineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Trans-2-Phenylcyclopropylamine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
DexmethylphenidateTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Trans-2-Phenylcyclopropylamine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit, Vet Approved
DiazoxideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Diazoxide.Approved
DibenzepinTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Dibenzepin.Experimental
Diethyl etherThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Diethyl ether.Experimental
diethylnorspermineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylpropionTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Difenoxin.Approved, Illicit
DihydralazineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Trans-2-Phenylcyclopropylamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Trans-2-Phenylcyclopropylamine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Trans-2-Phenylcyclopropylamine.Experimental, Illicit
DiltiazemTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Trans-2-Phenylcyclopropylamine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
DipivefrinThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Dipivefrin.Approved
DisopyramideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Dixyrazine.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Doramectin.Vet Approved
DorzolamideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Dorzolamide.Approved
DosulepinTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Dosulepin.Approved
DoxapramTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Doxepin.Approved
DoxylamineTrans-2-Phenylcyclopropylamine may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Trans-2-Phenylcyclopropylamine.Experimental, Illicit
DroxidopaThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Droxidopa.Approved, Investigational
DulaglutideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Trans-2-Phenylcyclopropylamine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Trans-2-Phenylcyclopropylamine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Efavirenz.Approved, Investigational
EfonidipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Eltanolone.Investigational
EmpagliflozinTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Endralazine.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
EpanololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EpoprostenolTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Eprosartan.Approved
ErgotamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Ergotamine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Escitalopram.Approved, Investigational
EsmirtazapineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Esmirtazapine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Trans-2-Phenylcyclopropylamine.Approved
EthanolTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Trans-2-Phenylcyclopropylamine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Trans-2-Phenylcyclopropylamine.Illicit, Vet Approved
ExenatideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Felbamate.Approved
FelodipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FenoldopamTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit, Investigational, Vet Approved
Ferulic acidTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Ferulic acid.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Trans-2-Phenylcyclopropylamine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Trans-2-Phenylcyclopropylamine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Formoterol.Approved, Investigational
FosinoprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit, Investigational
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Trans-2-Phenylcyclopropylamine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Gepirone.Investigational
GliclazideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Glipizide.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
GlyburideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Guanadrel.Approved
GuanazodineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Guanfacine.Approved, Investigational
GuanoclorTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Guanoxan.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Trans-2-Phenylcyclopropylamine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
HarmalineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit, Investigational
HexamethoniumTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Trans-2-Phenylcyclopropylamine.Approved
HydracarbazineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Hydracarbazine.Experimental
HydralazineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Hydromorphone.Approved, Illicit
HydroxyamphetamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Iloperidone.Approved
ImidaprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Indalpine.Investigational, Withdrawn
IndapamideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Indapamide.Approved
IndenololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Indenolol.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Indiplon.Investigational
IndoraminTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Trans-2-Phenylcyclopropylamine.Approved
IprindoleTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Iprindole.Experimental
IproclozideTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.Withdrawn
IrbesartanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Isoprenaline.Approved
IsradipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Isradipine.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
KetanserinTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Trans-2-Phenylcyclopropylamine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ketobemidone.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Trans-2-Phenylcyclopropylamine.Approved, Nutraceutical, Withdrawn
LabetalolTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Labetalol.Approved
LacidipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Lamotrigine.Approved, Investigational
LatanoprostTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Trans-2-Phenylcyclopropylamine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Levomilnacipran.Approved
LevonordefrinTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Trans-2-Phenylcyclopropylamine.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Levosalbutamol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Linezolid.Approved, Investigational
LinsidomineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Lofentanil.Illicit
LofepramineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Lofepramine.Experimental
LofexidineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Trans-2-Phenylcyclopropylamine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Lormetazepam.Approved
LosartanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Losartan.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Trans-2-Phenylcyclopropylamine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Trans-2-Phenylcyclopropylamine.Approved
MacitentanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Macitentan.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
ManidipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Trans-2-Phenylcyclopropylamine.Approved
MebanazineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Mebicar.Experimental
MecamylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Mecamylamine.Approved
MecaserminTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Trans-2-Phenylcyclopropylamine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Melperone.Approved, Investigational
MephedroneTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Mephedrone.Investigational
MephentermineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Meptazinol.Experimental
MequitazineTrans-2-Phenylcyclopropylamine may increase the anticholinergic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
MetaraminolTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Metaxalone.Approved
MetforminTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
MethamphetamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Trans-2-Phenylcyclopropylamine.Approved
MethoserpidineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational, Vet Approved
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Trans-2-Phenylcyclopropylamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Methsuximide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Methylecgonine.Experimental
Methylene blueTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Trans-2-Phenylcyclopropylamine.Approved
MetipranololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Metipranolol.Approved
MetolazoneTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Metolazone.Approved
MetoprololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineTrans-2-Phenylcyclopropylamine may increase the sedative activities of Metyrosine.Approved
MianserinTrans-2-Phenylcyclopropylamine may increase the neurotoxic activities of Mianserin.Approved, Investigational
MibefradilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
MidodrineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Midodrine.Approved
MidomafetamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Midomafetamine.Experimental, Illicit, Investigational
MifepristoneTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Milnacipran.Approved
MinaprineMinaprine may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.Approved, Investigational
MinoxidilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Minoxidil.Approved
MirtazapineTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDATrans-2-Phenylcyclopropylamine may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Moclobemide.Approved
MoexiprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Trans-2-Phenylcyclopropylamine.Approved
MorphineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Morphine.Approved, Investigational
MoxonidineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Muzolimine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.Approved, Investigational
NadololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nadolol.Approved
NaftopidilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Trans-2-Phenylcyclopropylamine.Approved
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
NateglinideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Nefazodone.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.Withdrawn
NicardipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nicardipine.Approved
NicorandilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nimodipine.Approved
NisoldipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Trans-2-Phenylcyclopropylamine.Approved
NitrendipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
NorepinephrineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Norepinephrine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Nortriptyline.Approved
OctamoxinTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
OlmesartanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Olopatadine.Approved
OmapatrilatTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Omapatrilat.Investigational
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Trans-2-Phenylcyclopropylamine.Approved
OpipramolTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Opium.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Orciprenaline.Approved
OrphenadrineTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Trans-2-Phenylcyclopropylamine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Trans-2-Phenylcyclopropylamine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Trans-2-Phenylcyclopropylamine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Trans-2-Phenylcyclopropylamine.Approved
ParaldehydeTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Pargyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Paroxetine.Approved, Investigational
PenbutololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Penfluridol.Experimental
PentamidineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
PentoliniumTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Pentolinium.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.Approved
PerazineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Perazine.Investigational
PergolideThe metabolism of Pergolide can be decreased when combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Trans-2-Phenylcyclopropylamine.Approved
PethidineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Phenazocine.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Phenibut.Experimental
PheniprazineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Trans-2-Phenylcyclopropylamine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Phenoperidine.Experimental
PhenoxybenzamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Phenoxyethanol.Approved
PhenoxypropazineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Phenytoin.Approved, Vet Approved
PholcodinePholcodine may increase the serotonergic activities of Trans-2-Phenylcyclopropylamine.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Trans-2-Phenylcyclopropylamine.Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Trans-2-Phenylcyclopropylamine.Approved
PinacidilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Pindolol.Approved
PioglitazoneTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Pipotiazine.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Piritramide.Investigational
PirlindolePirlindole may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.Approved
PivhydrazineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenTrans-2-Phenylcyclopropylamine may increase the anticholinergic activities of Pizotifen.Approved
Platelet Activating FactorTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Pomalidomide.Approved
PramipexoleTrans-2-Phenylcyclopropylamine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
PrazosinTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Trans-2-Phenylcyclopropylamine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational, Vet Approved
ProcarbazineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Procarbazine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Propoxycaine.Approved
PropranololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Proxibarbal.Experimental
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Trans-2-Phenylcyclopropylamine.Investigational
PSD502The risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with PSD502.Investigational
PseudoephedrineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Trans-2-Phenylcyclopropylamine.Approved
QuinaprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ramelteon.Approved, Investigational
RamiprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trans-2-Phenylcyclopropylamine.Approved
RemikirenTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Trans-2-Phenylcyclopropylamine.Approved, Withdrawn
RepaglinideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Reserpine.Approved, Investigational
RilmenidineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Riociguat.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ritanserin.Investigational
RitobegronTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ritodrine.Approved, Investigational
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Trans-2-Phenylcyclopropylamine.Approved
RomifidineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Romifidine.Vet Approved
RopiniroleTrans-2-Phenylcyclopropylamine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Trans-2-Phenylcyclopropylamine.Approved
RosiglitazoneTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RotigotineTrans-2-Phenylcyclopropylamine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Trans-2-Phenylcyclopropylamine.Approved
SafrazineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Salmeterol.Approved
SaprisartanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
SelegilineSelegiline may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.Approved, Investigational, Vet Approved
SelexipagTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Selexipag.Approved
SepranoloneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
SitagliptinTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.Approved
SpiraprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Spirapril.Approved
StiripentolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
SulfadiazineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Sultopride.Experimental
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
SunitinibTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuvorexantTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TalinololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Talinolol.Investigational
TandospironeThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tasimelteon.Approved
TelmisartanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Trans-2-Phenylcyclopropylamine.Approved
TemocaprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Terbutaline.Approved
TerlipressinTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Terlipressin.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Trans-2-Phenylcyclopropylamine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tetrodotoxin.Investigational
TetryzolineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Tetryzoline.Approved
ThalidomideTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Trans-2-Phenylcyclopropylamine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Trans-2-Phenylcyclopropylamine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tiagabine.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tiapride.Approved, Investigational
TiboloneTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tilidine.Experimental
TimololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tizanidine.Approved
TolazamideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Trans-2-Phenylcyclopropylamine.Approved, Withdrawn
TolonidineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Topiramate.Approved
TorasemideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Trans-2-Phenylcyclopropylamine.Approved, Investigational
TrandolaprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Trandolapril.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Trans-2-Phenylcyclopropylamine.Approved
TravoprostTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
TreprostinilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Trans-2-Phenylcyclopropylamine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Trans-2-Phenylcyclopropylamine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Trans-2-Phenylcyclopropylamine.Approved, Vet Approved
TrimazosinTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Triprolidine.Approved
UnoprostoneTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Unoprostone.Approved
UrapidilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Urapidil.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
ValsartanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Valsartan.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Trans-2-Phenylcyclopropylamine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Vigabatrin.Approved
VilanterolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Trans-2-Phenylcyclopropylamine.Approved
VincamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Xenon.Experimental
XipamideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Xylazine.Vet Approved
XylometazolineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineThe therapeutic efficacy of Trans-2-Phenylcyclopropylamine can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Trans-2-Phenylcyclopropylamine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Trans-2-Phenylcyclopropylamine.Approved
ZofenoprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Zolazepam.Vet Approved
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
ZolpidemTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Trans-2-Phenylcyclopropylamine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Trans-2-Phenylcyclopropylamine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Vithal Jagannath Rajadhyaksha, "Method of synthesis of trans-2-phenylcyclopropylamine." U.S. Patent US4016204, issued October, 1964.

US4016204
General References
Not Available
External Links
PubChem Compound
11861988
PubChem Substance
46506494
ChemSpider
10036445
ChEBI
131517
HET
TPA

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0104 mg/mLALOGPS
logP-1.6ALOGPS
logP1.34ChemAxon
logS-4.2ALOGPS
pKa (Strongest Basic)9.62ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area27.64 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity52.99 m3·mol-1ChemAxon
Polarizability15.83 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9819
Blood Brain Barrier+0.9453
Caco-2 permeable+0.7871
P-glycoprotein substrateNon-substrate0.8338
P-glycoprotein inhibitor INon-inhibitor0.9558
P-glycoprotein inhibitor IINon-inhibitor0.9827
Renal organic cation transporterNon-inhibitor0.8684
CYP450 2C9 substrateNon-substrate0.7997
CYP450 2D6 substrateNon-substrate0.8768
CYP450 3A4 substrateNon-substrate0.7287
CYP450 1A2 substrateInhibitor0.8593
CYP450 2C9 inhibitorNon-inhibitor0.8734
CYP450 2D6 inhibitorNon-inhibitor0.6988
CYP450 2C19 inhibitorInhibitor0.8154
CYP450 3A4 inhibitorNon-inhibitor0.9587
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6521
Ames testNon AMES toxic0.9213
CarcinogenicityNon-carcinogens0.721
BiodegradationReady biodegradable0.8237
Rat acute toxicity2.4558 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9604
hERG inhibition (predictor II)Non-inhibitor0.9333
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
Aralkylamines
Alternative Parents
Benzene and substituted derivatives / Organopnictogen compounds / Monoalkylamines / Hydrocarbon derivatives / Organic cations
Substituents
Aralkylamine / Benzenoid / Monocyclic benzene moiety / Organopnictogen compound / Hydrocarbon derivative / Primary amine / Primary aliphatic amine / Organic cation / Aromatic homomonocyclic compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serine-type endopeptidase activity
Specific Function
Has activity against the synthetic substrates Boc-Phe-Ser-Arg-Mec, Boc-Leu-Thr-Arg-Mec, Boc-Gln-Ala-Arg-Mec and Boc-Val-Pro-Arg-Mec. The single-chain form is more active than the two-chain form aga...
Gene Name
PRSS1
Uniprot ID
P07477
Uniprot Name
Trypsin-1
Molecular Weight
26557.88 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on December 01, 2017 15:01